Effects of emphysema and training on glutathione oxidation in the hamster diaphragm.

Loading of skeletal muscles is associated with increased generation of oxidants, which in turn may impair muscle contractility. We investigated whether the load on the hamster diaphragm imposed by pulmonary emphysema induces oxidative stress, as indicated by glutathione oxidation, and whether the degree of glutathione oxidation is correlated with contractility of the diaphragm. In addition, the effect of 12 wk of treadmill exercise training on contractility and glutathione content in the normal (NH) and emphysematous hamster (EH) diaphragm was investigated. Training started 6 mo after elastase instillation. After the training period, glutathione content and in vitro contractility of the diaphragm were determined. Twitch force and maximal tetanic force were significantly reduced (by approximately 30 and approximately 15%, respectively) in EH compared with NH. In sedentary hamsters, the GSSG-to-GSH ratio was significantly elevated in the EH compared with the NH diaphragm. A significant inverse correlation was found between GSSG-to-GSH ratio and twitch force in the diaphragm (P < 0. 01). Training improved maximal tetanic force and reduced fatigability of the EH diaphragm but did not alter its glutathione content. In conclusion, 1) emphysema induces oxidative stress in the diaphragm, 2) training improves the contractile properties of the EH diaphragm, and 3) this improvement is not accompanied by changes in glutathione redox status.     

Effect of clenbuterol on sarcoplasmic reticulum function in single skinned mammalian skeletal muscle fibers

We examined the effect of the₂-agonist clenbuterol (50 µM)on depolarization-induced force responses and sarcoplasmic reticulum (SR) function in muscle fibers of the rat (Rattusnorvegicus; killed by halothane overdose) that had beenmechanically skinned, rendering the₂-agonist pathway inoperable.Clenbuterol decreased the peak of depolarization-induced forceresponses in the extensor digitorum longus (EDL) and soleus fibers to77.2 ± 9.0 and 55.6 ± 5.4%, respectively, ofcontrols. The soleus fibers did not recover. Clenbuterol significantlyand reversibly reduced SR Ca²⁺loading in EDL and soleus fibers to 81.5 ± 2.8 and 78.7 ± 4.0%, respectively, of controls. Clenbuterol also producedan ~25% increase in passive leak ofCa²⁺ from the SR of the EDL andsoleus fibers. These results indicate that clenbuterol has directeffects on fast- and slow-twitch skeletal muscle, in the absence of the₂-agonist pathway. Theincreased Ca²⁺ leak in the triadregion may lead to excitation-contraction coupling damage in the soleusfibers and could also contribute to the anabolic effect of clenbuterolin vivo.

     

Beta 2-agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol

Potential treatments for skeletal muscle wasting and weakness ideally possess both anabolic and ergogenic properties. Although the beta(2)-adrenoceptor agonist clenbuterol has well-characterized effects on skeletal muscle, less is known about the therapeutic potential of the related beta(2)-adrenoceptor agonist fenoterol. We administered an equimolar dose of either clenbuterol or fenoterol to rats for 4 wk to compare their effects on skeletal muscle and tested the hypothesis that fenoterol would produce more powerful anabolic and ergogenic effects. Clenbuterol treatment increased fiber cross-sectional area (CSA) by 6% and maximal isometric force (P(o)) by 20% in extensor digitorum longus (EDL) muscles, whereas fiber CSA in soleus muscles decreased by 3% and P(o) was unchanged, compared with untreated controls. In the EDL muscles, fenoterol treatment increased fiber CSA by 20% and increased P(o) by 12% above values achieved after clenbuterol treatment. Soleus muscles of fenoterol-treated rats exhibited a 13% increase in fiber CSA and a 17% increase in P(o) above that of clenbuterol-treated rats. These data indicate that fenoterol has greater effects on the functional properties of rat skeletal muscles than clenbuterol.     

Contractile properties of clenbuterol-treated mdx muscle are enhanced by low-intensity swimming

Hayes, Alan, and David A. Williams. Contractileproperties of clenbuterol-treated mdxmuscle are enhanced by low-intensity swimming. J. Appl. Physiol. 82(2): 435-439, 1997.The₂-agonist clenbuterol haspotent anabolic properties in normal and denervated muscle and, assuch, may be of use in muscle wasting diseases such as musculardystrophy. However, potential side effects such as the transformationof the fiber type pool toward increased proportions of fast-twitchfibers must be balanced with the beneficial anabolic properties. In thepresent report, we clearly show that extensor digitorum longus andsoleus muscles from dystrophic mdx mice exposed to a combination of clenbuterol and low-intensity endurance swimming exercise did not undergo the slow- to fast-twitch fiber transformations caused by clenbuterol administration alone, yetincreases in the force-generating capacity of the soleus (30-40%) that resulted from the clenbuterol treatment were maintained after theswimming program. The increased sensitivity of dystrophin-deficient dystrophic muscle to clenbuterol and low-intensity exercise that isevident in this study may have therapeutic implications in thetreatment of muscle wasting diseases.

     

Cellular basis for contractile dysfunction in the diaphragm from a rabbit infarct model of heart failure

Abnormal respiratory muscle function isthought to contribute to breathlessness and exercise intolerance inheart failure but little is known about possible alterations in thefunction of such muscle. We have measured tetanic force andintracellular Ca²⁺ concentration([Ca²⁺]_i) in isolated, arteriallyperfused hemidiaphragm preparations from a rabbit coronary arteryligation model of heart failure. Increasing stimulation frequency(10-100 Hz) caused a progressive increase of force and[Ca²⁺]_i in control preparations,whereas force and [Ca²⁺]_i onlyincreased between 10 and 25 Hz stimulation (decreasing at higherfrequencies) in preparations from ligated animals. Cyclopiazonic acidproduced a dose-dependent shift in the relationship between stimulationfrequency and [Ca²⁺]_i in controlpreparations that was similar to the shift observed in the diaphragm ofcoronary-ligated animals. These data indicate that the in vitrocontractile characteristics of the diaphragm are significantly alteredin our model and that altered[Ca²⁺]_i regulation contributes tothe reduced diaphragm strength observed in heart failure.

     

Enhancement of hybrid-fiber types in rat soleus muscle after clenbuterol administration during hindlimb unloading

Our objective was to determine the effects of a clenbuterol (CB) treatment orally administered (2 mg per kg) to rats submitted to 14 days of hindlimb unloading (HU). The morphological and the contractile properties as well as the myosin heavy chain isoforms contained in each fiber type were determined in whole soleus muscles. As classically described after HU, a decrease in muscle wet weight and in body mass associated with a loss of muscular force, an evolution of the contractile parameters towards those of a fast muscle type, and the emergence of fast myosin heavy chain isoforms were observed. The CB treatment in the HU rats helped reduce the decrease in 1) muscle and body weights, 2) force and 3) the proportion of slow fibers, without preventing the emergence of fast myosin isoforms. Clenbuterol induced a complex remodelling of the muscle typing promoting the combination of both slow and fast myosin isoforms within one fiber. To conclude, our data demonstrate that CB administration partially counteracts the effects produced by HU, and they allow us to anticipate advances in the treatment of muscular atrophy.     

Decreased monocarboxylate transporter 1 in rat soleus and EDL muscles exposed to clenbuterol.

We hypothesized that a shift in muscle fiber type induced by clenbuterol would change monocarboxylate transporter 1 (MCT1) content and activity of lactate dehydrogenase (LDH) and isoform pattern and shift myosin heavy chain (MHC) pattern in soleus (Sol) and extensor digitorum longus (EDL) of male rats. In the clenbuterol-administered rats (2.0 mg x kg(-1) x day(-1) subcutaneously for 4 wk), the ratio of muscle weight to body weight increased in the Sol (P < 0.05) and the EDL (P < 0.01). Clenbuterol induced the appearance of fast MHC(2D) and decreased slow MHC(1) in Sol (13%) but had no effect on EDL. The MHC pattern of Sol changed from slow to fast type. Clenbuterol increased LDH-specific activity (P < 0.01) and the ratio of the muscle-type isozyme of LDH to the heart type (P < 0.05) in Sol. The LDH total activity of the EDL muscle was also increased (P < 0.05). Furthermore, MCT1 content significantly (P < 0.05) decreased in both Sol and EDL (27 and 52%, respectively). This study suggests that clenbuterol might mediate the shift of MHC from slow to fast type and the changes in the regulation of lactate metabolism. Novel to this study is the observation that clenbuterol decreases MCT1 content in the hindlimb muscles and that the decrease in MCT1 is not muscle-type specific. It may suggest that the genetic expressions of individual factors involving slow-type MHC, heart-type isozyme of LDH, and MCT1 are associated with one another but are regulated independently.     

Isotonic contractile and fatigue properties of developing rat diaphragm muscle

Postnatal transitions in myosin heavy chain (MHC) isoformexpression were found to be associated with changes in both isometric and isotonic contractile properties of rat diaphragm muscle(Dia_m). Expression of MHC_neo predominated inneonatal Dia_m fibers but was usually coexpressed withMHC_slow or MHC_2A isoforms. Expression ofMHC_neo disappeared by day 28. Expression ofMHC_2X and MHC_2B emerged at day 14 andincreased thereafter. Associated with these MHC transitions in theDia_m, maximum isometric tetanic force (P_o), maximum shortening velocity, and maximum power output progressively increased during early postnatal development. Maximum power output ofthe Dia_m occurred at ~40% P_o at days0 and 7 and at ~30% P_o in older animals.Susceptibility to isometric and isotonic fatigue, defined as a declinein force and power output during repetitive activation, respectively,increased with maturation. Isotonic endurance time, defined as the timefor maximum power output to decline to zero, progressively decreasedwith maturation. In contrast, isometric endurance time, defined as thetime for force to decline to 30-40% P_o, remained>300 s until after day 28. We speculate that with thepostnatal transition to MHC_2X and MHC_2Bexpression energy requirements for contraction increase, especiallyduring isotonic shortening, leading to a greater imbalance betweenenergy supply and demand.

     

Mofification of body composition by clenbuterol in normal and dystrophic (mdx) mice

Female dystrophic mice (mdx on C57 Black background) gained weight more rapidly than age-matched controls and had a higher body fat content (% body weight), a slightly lower protein content and a reduced mass of muscle. Chronic treatment (21 d) of the mice with the ₂-agonist clenbuterol stimulated weight gain in both genotypes without affecting energy intake. Clenbuterol increased the mass of the gastrocnemius and soleus muscle by 13% and 29% in normal and dystrophic mice, respectively, and raised body protein but depressed body fat. Body water and energy content were unaffected by clenbuterol, but the ratio of protein to fat in the carcasses was enhanced by 17% in normal and 56% in dystrophic mice following clenbuterol treatment. Thus, the ₂-agonist restored the body composition of dystrophic mice to normal and enhanced the protein to fat ratio in both these and normal mice.     

Chronic effects of β2 agonists on body composition and protein synthesis in the rat

Chronic treatment of rats with the ₂-adrenergic agonists clenbuterol and fenoterol over 16–19 d raised energy intake, expenditure, and body weight gain but did not affect fat or energy deposition, and body protein gain was increased by 50 and 18%, respectively. Both drugs increased the protein content and mitochondrial GDP-binding capacity of brown adipose tissue. Clenbuterol did not affect plasma insulin, growth hormone, or triiodothyronine levels, although insulin levels were reduced by fenoterol. Both drugs caused hypertrophy of skeletal muscle (gastrocnemius), and muscle protein synthesis in vivo (fractional rate) was elevated by 34 and 26% in clenbuterol and fenoteroltreated rats, respectively.     

Peak power output is maintained in rabbit psoas and rat soleus single muscle fibers when CTP replaces ATP

The chemomechanicalcoupling mechanism in striated muscle contraction was examined bychanging the nucleotide substrate from ATP to CTP. Maximum shorteningvelocity [extrapolation to zero force from force-velocity relation(V_max) andslope of slack test plots (V₀)], maximumisometric force (P_o), power, andthe curvature of the force-velocity curve[a/P_o(dimensionless parameter inversely related to the curvature)] weredetermined during maximumCa²⁺-activated isotoniccontractions of fibers from fast rabbit psoas and slow rat soleusmuscles by using 0.2 mM MgATP, 4 mM MgATP, 4 mM MgCTP, or 10 mM MgCTPas the nucleotide substrate. In addition to a decrease in the maximumCa²⁺-activated force in both fibertypes, a change from 4 mM ATP to 10 mM CTP resulted in a decrease inV_max in psoasfibers from 3.26 to 1.87 muscle length/s. In soleus fibers,V_max was reduced from 1.94 to 0.90 muscle length/s by this change in nucleotide. Surprisingly, peak power was unaffected in either fiber type by thechange in nucleotide as the result of a three- to fourfold decrease inthe curvature of the force-velocity relationship. The results areinterpreted in terms of the Huxley model of muscle contraction as anincrease in f₁and g₁ coupled toa decrease in g₂(where f₁ is therate of cross-bridge attachment and g₁ andg₂ are rates ofdetachment) when CTP replaces ATP. This adequately accounts for theobserved changes in P_o,a/P_o,and V_max.However, the two-state Huxley model does not explicitly reveal thecross-bridge transitions that determine curvature of the force-velocityrelationship. We hypothesize that a nucleotide-sensitive transitionamong strong-binding cross-bridge states followingP_i release, but before the release of the nucleotide diphosphate, underlies the alterations ina/P_o reported here.

     

Gender-specific effects of dexamethasone treatment on rat diaphragm structure and function

Prezant, D. J., M. L. Karwa, B. Richner, D. Maggiore, E. I. Gentry, and J. Cahill. Gender-specific effects of dexamethasone treatment on rat diaphragm structure and function. J. Appl. Physiol. 82(1): 125-133, 1997.The effectsof long-term dexamethasone treatment on diaphragm muscle were studiedin female and male rats. Compared with pair-fed control animals,dexamethasone treatment did not significantly affect estrous cycling orpeak serum estradiol levels; however, testosterone levels weresignificantly increased in females and decreased in males.Dexamethasone significantly reduced body and costal diaphragm weights,but to a lesser extent in females than in males. Reductions indiaphragm weight were proportional to reductions in body weight. Infemales and males, dexamethasone treatment significantly decreaseddiaphragm fiber (types I and II) cross-sectional area and the relativeexpression of myosin heavy chain isoform 2B. With the exception of typeI fiber atrophy, these changes occurred to a lesser extent in females.Dexamethasone did not significantly affect specific forces.Dexamethasone significantly increased twitch one-half relaxation timeand fatigue resistance indexes in males but not in females. Inconclusion, the effects of long-term dexamethasone treatment weregender specific, with significantly fewer effects in females, andchanges in serum testosterone levels were associated with thesefindings.

     

Effects of beta 2-agonist administration and exercise on contractile activation of skeletal muscle fibers

Lynch, Gordon S., Alan Hayes, Siun P. Campbell, and David A. Williams. Effects of₂-agonist administration andexercise on contractile activation of skeletal muscle fibers.J. Appl. Physiol. 81(4):1610-1618, 1996.Clenbuterol, a₂-adrenoceptor agonist, hastherapeutic potential for the treatment of muscle-wasting diseases, yetits effects, especially at the single-fiber level, have not been fullycharacterized. Male C57BL/10 mice were allocated to three groups:Control-Treated mice were administered clenbuterol (2 mg ^· kg^{1 ·} day¹)via their drinking water for 15 wk; Trained-Treated mice underwent low-intensity training (unweighted swimming, 5 days/wk, 1 h/day) inaddition to receiving clenbuterol; and Control mice were sedentary anduntreated. Contractile characteristics were determined on membrane-permeabilized fibers from the extensor digitorum longus (EDL)and soleus muscles. Fast fibers from the EDL and soleus muscles ofTreated mice exhibited decreases inCa²⁺ sensitivity. Enduranceexercise offset clenbuterol's effects, demonstrated by similarCa²⁺ sensitivities in theTrained-Treated and Control groups. Long-term clenbuterol treatment didnot affect the normalized maximal tension of fast or slow fibers butincreased the proportion of fast fibers in the soleus muscle. Trainingincreased the proportion of fibers with high and intermediate succinatedehydrogenase activity in the EDL and soleus muscles, respectively. Ifclenbuterol is to be used for treating muscle-wasting disorders, someform of low-intensity exercise might be encouraged such thatpotentially deleterious slow-to-fast fiber type transformations areminimized. Indeed, in the mouse, low-intensity exercise appears toprevent these effects.

     

Effect of P(i) on unloaded shortening velocity of slow and fast mammalian muscle fibers

Chemically skinned muscle fibers,prepared from the rat medial gastrocnemius and soleus, were subjectedto four sequential slack tests in Ca²⁺-activating solutionscontaining 0, 15, 30, and 0 mM added P_i. P_i (15 and 30 mM) had no effect on the unloaded shortening velocity (V_o) of fibers expressing type IIb myosin heavychain (MHC). For fibers expressing type I MHC, 15 mM P_i didnot alter V_o, whereas 30 mM P_ireduced V_o to 81 ± 1% of the original 0 mM P_i value. This effect was readily reversible whenP_i was lowered back to 0 mM. These results are notcompatible with current cross-bridge models, developed exclusively fromdata obtained from fast fibers, in which V_o isindependent of P_i. The response of the type I fibers at 30 mM P_i is most likely the result of increased internal drag opposing fiber shortening resulting from fiber type-specific effects ofP_i on cross bridges, the thin filament, or therate-limiting step of the cross-bridge cycle.

     

Effect of continuous and intermittent clenbuterol feeding on rat growth rate and muscle

1. The growth response to clenbuterol is a dynamic process. 2. Body weight gain is stimulated within two days of treatment and the effect attenuates by two weeks of treatment. 3. Intermittent feeding prevents the attenuation of the growth response. 4. Muscle weight increased 14-22% by both feeding regimens. 5. Clenbuterol decreased cathepsin B activity in the EDL and gastrocnemius and increased the activity in the soleus after two weeks of continuous clenbuterol treatment.     

Short- and long-term effects of testosterone on diaphragm in castrated and normal male rats

Prezant, David J., Manoj L. Karwa, Helen H. Kim, DianeMaggiore, Virginia Chung, and David E. Valentine. Short- and long-term effects of testosterone on diaphragm in castrated and normalmale rats. J. Appl. Physiol. 82(1):134-143, 1997.The effects of short- and long-term testosteroneabsence or treatment on the diaphragm were studied in castrated andsexually normal male rats. Compared with control rats (untreated normalmales), testosterone absence or treatment did not significantly affect costal weight. In untreated castrated males, there were significant decreases in specific forces, type II fiber cross-sectional area, andmyosin heavy chain (MHC) isoform 2B after 2.5 wk. In castrated malesthat received testosterone, there were significant increases inspecific forces, type II total fiber proportional area, and relativeexpression of all adult diaphragm fast MHC isoforms(MHC-2_all) after 2.5 wk. In normal males thatreceived testosterone, the only significant finding was an increase inMHC-2B after 2.5 wk. Across all groups, there was close correlationbetween increases in maximum tetanic forces and MHC-2_all.Changes in diaphragm function and composition were closely related tochanges in serum testosterone levels at 2.5 wk. The lack of significantchange in diaphragm function at 10 wk occurred despite changes in serumtestosterone levels and diaphragm composition similar to those at 2.5 wk. These findings support our hypothesis that the effects oftestosterone are dependent on basal circulating androgen levels andstudy duration.

     

Contraction-induced injury to single muscle fibers: velocity of stretch does not influence the force deficit

We tested the null hypothesis that theseverity of injury to single muscle fibers following a singlepliometric (lengthening) contraction is not dependent on the velocityof stretch. Each single permeabilized fiber obtained from extensordigitorum longus muscles of rats was maximally activated and thenexposed to a single stretch of either 5, 10, or 20% strain [%of fiber length (L_f)] ata velocity of 0.5, 1.0, or 2.0 L_f /s. Theforce deficit, the difference between maximum tetanic isometric force(P_o) before and after the stretch expressed as apercentage of the control value forP_o before the stretch, provided anestimate of the magnitude of muscle injury. Despite a fourfold rangefrom the lowest to the highest velocities, force deficits were notdifferent among stretches of the same strain. At stretches of 20%strain, even an eightfold range of velocities produced no difference inthe force deficit, although 40% of the fibers were torn apart at a velocity of 4 L_f /s. We conclude that, withinthe range of velocities tolerated by single permeabilized fibers, theseverity of contraction-induced injury is not related to the velocityof stretch.

     

The myostatin null mutation and clenbuterol administration elicit additive effects in mice

In mice, the myostatin (Mstn) null mutation and treatment with clenbuterol both increase muscle growth and decrease fat mass. Our objective was to determine whether mechanistic overlap exists by administering clenbuterol to Mstn null mice. Male Mstn null and wild-type mice of similar genetic backgrounds received either 0 (control) or 20 p.p.m. clenbuterol in tap water free choice for 14 days. Several traits were measured to estimate muscle and fat growth. The Mstn null mutation resulted in increased body and empty carcass weight, increased muscle weights and decreased fat pad weights. Fat content was reduced and protein content was increased in the empty carcasses of Mstn null mice. Similarly, treatment with clenbuterol resulted in increased body and empty carcass weight, increased muscle weights and reduced fat pad weights. Fat content of empty carcasses and viscera was reduced and protein content of empty carcasses was increased with clenbuterol treatment. A significant interaction of genotype and clenbuterol treatment would indicate an altered responsiveness of Mstn null mice to clenbuterol. However, only the weight of gastrocnemius muscles exhibited a significant (P = 0.01) interaction of genotype and clenbuterol treatment, indicating that Mstn null mice were less responsive to clenbuterol compared with wild-type mice. Thus, for all other traits, the impact of Mstn null mutation and clenbuterol treatment was completely additive. These data suggest that disruption of Mstn function does not alter the response of mice to β-adrenergic agonists.     

The effect of clenbuterol on body composition in spontaneously eating tumour-bearing mice

The aim of this study was to investigate the effect of a selective ₂-adrenoceptor agonist, clenbuterol, on body composition in tumour-bearing adult and growing mice. Therefore, adult female C57/BL6 mice (n=20) were inoculated subcutaneously with a 3-methylcholanthrene-induced sarcoma and divided into two identical groups. One group received injections twice a day of clenbuterol corresponding to 1 mg/kg body weight, the other group received sham injections. Growing mice (n=20) were similarly divided after tumour inoculation into one study group with clenbuterol injections and one control group. The growing animals were sacrificed on day 11 after commencement of treatment, the adult mice on day 16.Clenbuterol treatment had no statistically significant effect on accumulated food intake or body composition in the adult mice. However, fooe intake in these animals increased numerically compared to control animals after day 12 of the study. Tumour growth was also unaffected. The growing animals displayed an increased carcass dry weight with borderline significance (p=0.06) and an increased quadriceps muscle fat free dry weight after clenbuterol treatment. Tumour growth was not affected. Food intake measured on a daily basis was significantly increased in the growing clenbuterol treated animals and accumulated food intake was increased with a trend towards statistical significance (p=0.06). The results support the suggestion that treatment with a selective ₂-adrenoceptor agonist does not improve body composition in tumour-bearing adult mice relying on spontaneous food intake while growing animals may benefit from such treatment.